Cargando…
Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia
BACKGROUND: The relevance of recurrent molecular abnormalities in cytogenetically normal (CN) acute myeloid leukemia (AML) was recently acknowledged by the inclusion of molecular markers such as NPM1, FLT3, and CEBPA as a complement to cytogenetic information within both the World Health Organizatio...
Autores principales: | Yang, Wen-Chi, Tsai, Wan-Chi, Lin, Pai-Mei, Yang, Ming-Yu, Liu, Yi-Chang, Chang, Chao-Sung, Yu, Wen-Hui, Lin, Sheng-Fung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844465/ https://www.ncbi.nlm.nih.gov/pubmed/23941109 http://dx.doi.org/10.1186/1423-0127-20-58 |
Ejemplares similares
-
The Effects of Human BDH2 on the Cell Cycle, Differentiation, and Apoptosis and Associations with Leukemia Transformation in Myelodysplastic Syndrome
por: Yang, Wen-Chi, et al.
Publicado: (2020) -
Anti-Tumor Effects of BDH1 in Acute Myeloid Leukemia
por: Han, Fei, et al.
Publicado: (2021) -
Redefining prognostication of de novo cytogenetically normal acute myeloid leukemia in young adults
por: Tsui, Sze P., et al.
Publicado: (2020) -
Altered expression of imprinted genes in patients with cytogenetically normal‑acute myeloid leukemia: Implications for leukemogenesis and survival outcomes
por: Yang, Ming-Yu, et al.
Publicado: (2023) -
Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia
por: Hou, Hsin-An, et al.
Publicado: (2016)